Trial Profile
A Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9- Tetrahydrocannabinol/Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers/Fasting State
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain
- Focus Adverse reactions; First in man
- Sponsors Tetra Bio Pharma
- 23 Sep 2020 Results presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 20 Dec 2018 Results presented in the Tetra Bio Pharma media release.
- 01 Sep 2018 Results of the multiple ascending dose phase of the study (n=24) published in the Clinical Pharmacology in Drug Development Conference: 2018 Annual Meeting of the American College of Clinical Pharmacology